Use access key #2 to skip to page content.
$6.05 -0.02 (-0.33%)
11/21/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
***

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AMLN

Add Stock to Watchlist

What the Community Thinks

Total Members

299 Outperforms
48 Underperforms
 

All-Stars

52 Outperforms
21 Underperforms
 

Wall Street

6 Outperforms
4 Underperforms
 

Members bullish on AMLN are also bullish on:

Members bearish on AMLN are also bearish on:

Ticker Tags

Biotechnology (230), Nasdaq 100 (88), Small Cap (1354)
Suggest a tag

Amylin Pharmaceuticals, Inc. At A Glance

Current Price: $6.05
Last Trade Time: 11/21/2008 4:00 PM
Open: $6.15
Previous Close: $6.07
Daily Range: $5.50 - $6.22
52-Week Range: $5.80 - $39.90
Volume: 3,461,938
Market Cap: $835.34M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

AMLN VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for AMLN

More Headlines...

Top Bull Pitch

Recs

1

Amylin Pharmaceuticals, Inc. (AMLN)

Avatar fedja2 (29.08) Submitted: 10/06/08 4:32 AM

I am BUYing now, I SELL near 35$. And you ?

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Amylin Pharmaceuticals, Inc. (AMLN)

Avatar cubanrafter (< 20) Submitted: 9/04/08 8:42 AM

People are focusing on Pancreatitis.


The real issue is competition. Byetta is an adjunt therapy in uncontrolled patients. Now we have Januvia, who pretty much does the same thing, is oral and cheaper than Byetta. People do not like needles, diabetics will try everything oral before going...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 72 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (AMLN)

Avatar quinpeung (79.86) Submitted: 11/15/08 5:21 PM : Underperform Start Price: $7.49 AMLN Score: 7.13

The regulatory approval timeline for the diabetes drug exenatide LAR is delayed. Company recently layed off employees. Stock should continue to slide.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AMLN)

Avatar lemsilogram (< 20) Submitted: 11/15/08 2:18 AM : Outperform Start Price: $7.49 AMLN Score: -7.13

Exenatide LAR should come online in 2011. This will boost the bottom line.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (AMLN)

Avatar fedja2 (29.08) Submitted: 10/06/08 4:32 AM : Outperform Start Price: $17.79 AMLN Score: -36.77

I am BUYing now, I SELL near 35$. And you ?

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AMLN)

Avatar mjan706 (< 20) Submitted: 9/22/08 1:39 AM : Outperform Start Price: $21.33 AMLN Score: -32.50

An Icahn portfolio stock.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AMLN)

Avatar biopharminvestor (50.91) Submitted: 9/16/08 10:01 PM : Outperform Start Price: $21.46 AMLN Score: -35.16

Overreaction to the pancreatitis deaths (6). Diabetes space was hammered starting with Exubera withdrawal and other insulin or ODA's (perceived) safety problems. When this passes, the diabetes space will be more fairly valued. A huge growing epidemic that is poorly served by existing treatments.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 72 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE Expand All Pitches

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackJimCramer 85.65 10/23/08 Underperform 3W $11.34-46.65%-17.29%+29.36
TrackLazardCapit < 20 09/02/08 Outperform NS $22.40-72.99%-41.72%-31.27
TrackSoleil 83.71 08/27/08 Underperform NS $23.81-74.59%-40.55%+34.04
TrackIcahn 45.81 05/29/08 Outperform 1Y $31.68-80.90%-45.45%-35.45 Toggle the visibility of 60-Second Pitch and replies
TrackBMOCapital 86.58 04/22/08 Underperform NS $27.41-77.93%-45.07%+32.86
TrackEdwardOwens 99.48 09/30/07 Outperform NS $50.00-87.90%-50.30%-37.60 Toggle the visibility of 60-Second Pitch and replies
TrackGaryBSmith 79.82 05/25/07 Outperform 3W $44.91-86.53%-50.01%-36.52
TrackWRHambrecht < 20 03/13/07 Outperform NS $38.19-84.16%-46.01%-38.14
TrackLeerinkSwan 92.44 02/05/07 Outperform NS $39.00-84.49%-47.60%-36.88
TrackFirstAlbany 27.62 01/31/07 Underperform NS $38.93-84.46%-46.76%+37.70

Results 1 - 10 of 10  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links